Bluejay Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://bluejaytx.com
Clinical Trials
5
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Phase 2
Recruiting
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Drug: Brelovitug 300 mgDrug: Brelovitug 900 mgDrug: Delayed Treatment with Brelovitug 300mg
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Bluejay Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06907290
- Locations
- 🇺🇸
Garden Grove, Garden Grove, California, United States
🇺🇸Huntington Beach, Huntington Beach, California, United States
🇺🇸Long Beach, Long Beach, California, United States
News
No news found